Eduard M. Schulz

Graz, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

Elevated plasma anandamide levels in sclerotic chronic graft-versus-host disease highlight the endocannabinoid system as a potential therapeutic target.

Elevated plasma anandamide levels in sclerotic chronic graft-versus-host disease highlight the endocannabinoid system as a potential therapeutic target.

Journal: Bone marrow transplantation
Published: June 24, 2026

Comparison of outcomes after DA-EPOCH-R or GMALL high-intensity therapy for front-line treatment of Burkitt lymphoma: A retrospective cohort.

Comparison of outcomes after DA-EPOCH-R or GMALL high-intensity therapy for front-line treatment of Burkitt lymphoma: A retrospective cohort.

Journal: British journal of haematology
Published: June 08, 2026

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Journal: Transplantation and cellular therapy
Published: April 25, 2026

Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.

Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.

Journal: British journal of haematology
Published: April 25, 2026

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-versus-Host Disease.

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-versus-Host Disease.

Journal: Transplantation and cellular therapy
Published: February 23, 2026

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-Versus-Host Disease.

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-Versus-Host Disease.

Journal: Transplantation and cellular therapy
Published: February 23, 2026

Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.

Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.

Journal: Blood advances
Published: October 27, 2025

Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.

Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.

Journal: Blood advances
Published: October 27, 2025

Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance.

Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance.

Journal: Blood reviews
Published: May 09, 2025

Diagnostic approaches for haematopoietic cell transplantation-associated membranous nephropathy: Novel underutilized tools.

Diagnostic approaches for haematopoietic cell transplantation-associated membranous nephropathy: Novel underutilized tools.

Journal: British journal of haematology
Published: February 19, 2025

Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT.

Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT.

Journal: Blood
Published: January 28, 2025

A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned.

A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned.

Journal: British journal of haematology
Published: January 24, 2025
Showing 1-12 of 48

Last Updated: 09/26/2026